On Dec. 24, 2020, AIM ImmunoTech announced that the post-COVID-19 ﾓLong Haulerﾔ portion of the active AMP-511 Expanded Access Program (EAP) protocol received approval from the Institutional Review Board (IRB) for a public notification of potential patient enrollment.

Eligible patients enrolled in the trial receive treatment with AIMﾒs flagship pipeline drug Ampligen.